Histiocytoid Sweet syndrome may indicate leukemia cutis

A novel application of fluorescence in situ hybridization

Rahul N. Chavan, Mark A. Cappel, Rhett P. Ketterling, David A. Wada, Nicole M. Rochet, Ryan Knudson, Lawrence E. Gibson

Research output: Contribution to journalArticle

29 Citations (Scopus)

Abstract

Background In patients with malignancy-associated Sweet syndrome, a thorough evaluation for leukemia cutis should be considered. Objective We sought to describe the clinicopathologic characteristics of histiocytoid Sweet syndrome. Methods We retrospectively identified patients with histiocytoid Sweet syndrome at our institution from January 1992 through December 2010. We evaluated the underlying cutaneous infiltrate using immunohistochemistry and fluorescence in situ hybridization. Results We re-evaluated all 22 patients with hematologic malignancy-associated Sweet syndrome. Six patients had a monocytoid infiltrate that was consistent with histiocytoid Sweet syndrome; subsequent evaluation of these patients demonstrated cytogenetic abnormalities on prior bone-marrow biopsy specimens. Fluorescence in situ hybridization analysis was feasible in cutaneous specimens from 5 of the 6 patients and demonstrated the same cytogenetic abnormalities that were identified on prior bone-marrow biopsy specimens in 4 patients. Therefore, these 4 patients may have had a form of leukemia cutis. Limitations This was a retrospective study. Conclusion For patients with histiocytoid Sweet syndrome, an underlying hematologic malignancy, and a monocytoid infiltrate on biopsy specimen, fluorescence in situ hybridization of the cutaneous infiltrate may be beneficial to identify cytogenetic abnormalities that may indicate leukemia cutis.

Original languageEnglish (US)
Pages (from-to)1021-1027
Number of pages7
JournalJournal of the American Academy of Dermatology
Volume70
Issue number6
DOIs
StatePublished - 2014

Fingerprint

Sweet Syndrome
Fluorescence In Situ Hybridization
Leukemia
Chromosome Aberrations
Hematologic Neoplasms
Biopsy
Skin
Bone Marrow
Retrospective Studies
Immunohistochemistry

Keywords

  • cytogenetic abnormalities
  • fluorescence in situ hybridization analysis
  • histiocytoid Sweet syndrome
  • leukemia cutis
  • malignancy-associated Sweet syndrome
  • Sweet syndrome

ASJC Scopus subject areas

  • Dermatology

Cite this

Chavan, R. N., Cappel, M. A., Ketterling, R. P., Wada, D. A., Rochet, N. M., Knudson, R., & Gibson, L. E. (2014). Histiocytoid Sweet syndrome may indicate leukemia cutis: A novel application of fluorescence in situ hybridization. Journal of the American Academy of Dermatology, 70(6), 1021-1027. https://doi.org/10.1016/j.jaad.2014.01.874

Histiocytoid Sweet syndrome may indicate leukemia cutis : A novel application of fluorescence in situ hybridization. / Chavan, Rahul N.; Cappel, Mark A.; Ketterling, Rhett P.; Wada, David A.; Rochet, Nicole M.; Knudson, Ryan; Gibson, Lawrence E.

In: Journal of the American Academy of Dermatology, Vol. 70, No. 6, 2014, p. 1021-1027.

Research output: Contribution to journalArticle

Chavan, Rahul N. ; Cappel, Mark A. ; Ketterling, Rhett P. ; Wada, David A. ; Rochet, Nicole M. ; Knudson, Ryan ; Gibson, Lawrence E. / Histiocytoid Sweet syndrome may indicate leukemia cutis : A novel application of fluorescence in situ hybridization. In: Journal of the American Academy of Dermatology. 2014 ; Vol. 70, No. 6. pp. 1021-1027.
@article{f414f2f9c23445e2b29f909bf619a7ed,
title = "Histiocytoid Sweet syndrome may indicate leukemia cutis: A novel application of fluorescence in situ hybridization",
abstract = "Background In patients with malignancy-associated Sweet syndrome, a thorough evaluation for leukemia cutis should be considered. Objective We sought to describe the clinicopathologic characteristics of histiocytoid Sweet syndrome. Methods We retrospectively identified patients with histiocytoid Sweet syndrome at our institution from January 1992 through December 2010. We evaluated the underlying cutaneous infiltrate using immunohistochemistry and fluorescence in situ hybridization. Results We re-evaluated all 22 patients with hematologic malignancy-associated Sweet syndrome. Six patients had a monocytoid infiltrate that was consistent with histiocytoid Sweet syndrome; subsequent evaluation of these patients demonstrated cytogenetic abnormalities on prior bone-marrow biopsy specimens. Fluorescence in situ hybridization analysis was feasible in cutaneous specimens from 5 of the 6 patients and demonstrated the same cytogenetic abnormalities that were identified on prior bone-marrow biopsy specimens in 4 patients. Therefore, these 4 patients may have had a form of leukemia cutis. Limitations This was a retrospective study. Conclusion For patients with histiocytoid Sweet syndrome, an underlying hematologic malignancy, and a monocytoid infiltrate on biopsy specimen, fluorescence in situ hybridization of the cutaneous infiltrate may be beneficial to identify cytogenetic abnormalities that may indicate leukemia cutis.",
keywords = "cytogenetic abnormalities, fluorescence in situ hybridization analysis, histiocytoid Sweet syndrome, leukemia cutis, malignancy-associated Sweet syndrome, Sweet syndrome",
author = "Chavan, {Rahul N.} and Cappel, {Mark A.} and Ketterling, {Rhett P.} and Wada, {David A.} and Rochet, {Nicole M.} and Ryan Knudson and Gibson, {Lawrence E.}",
year = "2014",
doi = "10.1016/j.jaad.2014.01.874",
language = "English (US)",
volume = "70",
pages = "1021--1027",
journal = "Journal of the American Academy of Dermatology",
issn = "0190-9622",
publisher = "Mosby Inc.",
number = "6",

}

TY - JOUR

T1 - Histiocytoid Sweet syndrome may indicate leukemia cutis

T2 - A novel application of fluorescence in situ hybridization

AU - Chavan, Rahul N.

AU - Cappel, Mark A.

AU - Ketterling, Rhett P.

AU - Wada, David A.

AU - Rochet, Nicole M.

AU - Knudson, Ryan

AU - Gibson, Lawrence E.

PY - 2014

Y1 - 2014

N2 - Background In patients with malignancy-associated Sweet syndrome, a thorough evaluation for leukemia cutis should be considered. Objective We sought to describe the clinicopathologic characteristics of histiocytoid Sweet syndrome. Methods We retrospectively identified patients with histiocytoid Sweet syndrome at our institution from January 1992 through December 2010. We evaluated the underlying cutaneous infiltrate using immunohistochemistry and fluorescence in situ hybridization. Results We re-evaluated all 22 patients with hematologic malignancy-associated Sweet syndrome. Six patients had a monocytoid infiltrate that was consistent with histiocytoid Sweet syndrome; subsequent evaluation of these patients demonstrated cytogenetic abnormalities on prior bone-marrow biopsy specimens. Fluorescence in situ hybridization analysis was feasible in cutaneous specimens from 5 of the 6 patients and demonstrated the same cytogenetic abnormalities that were identified on prior bone-marrow biopsy specimens in 4 patients. Therefore, these 4 patients may have had a form of leukemia cutis. Limitations This was a retrospective study. Conclusion For patients with histiocytoid Sweet syndrome, an underlying hematologic malignancy, and a monocytoid infiltrate on biopsy specimen, fluorescence in situ hybridization of the cutaneous infiltrate may be beneficial to identify cytogenetic abnormalities that may indicate leukemia cutis.

AB - Background In patients with malignancy-associated Sweet syndrome, a thorough evaluation for leukemia cutis should be considered. Objective We sought to describe the clinicopathologic characteristics of histiocytoid Sweet syndrome. Methods We retrospectively identified patients with histiocytoid Sweet syndrome at our institution from January 1992 through December 2010. We evaluated the underlying cutaneous infiltrate using immunohistochemistry and fluorescence in situ hybridization. Results We re-evaluated all 22 patients with hematologic malignancy-associated Sweet syndrome. Six patients had a monocytoid infiltrate that was consistent with histiocytoid Sweet syndrome; subsequent evaluation of these patients demonstrated cytogenetic abnormalities on prior bone-marrow biopsy specimens. Fluorescence in situ hybridization analysis was feasible in cutaneous specimens from 5 of the 6 patients and demonstrated the same cytogenetic abnormalities that were identified on prior bone-marrow biopsy specimens in 4 patients. Therefore, these 4 patients may have had a form of leukemia cutis. Limitations This was a retrospective study. Conclusion For patients with histiocytoid Sweet syndrome, an underlying hematologic malignancy, and a monocytoid infiltrate on biopsy specimen, fluorescence in situ hybridization of the cutaneous infiltrate may be beneficial to identify cytogenetic abnormalities that may indicate leukemia cutis.

KW - cytogenetic abnormalities

KW - fluorescence in situ hybridization analysis

KW - histiocytoid Sweet syndrome

KW - leukemia cutis

KW - malignancy-associated Sweet syndrome

KW - Sweet syndrome

UR - http://www.scopus.com/inward/record.url?scp=84901197541&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84901197541&partnerID=8YFLogxK

U2 - 10.1016/j.jaad.2014.01.874

DO - 10.1016/j.jaad.2014.01.874

M3 - Article

VL - 70

SP - 1021

EP - 1027

JO - Journal of the American Academy of Dermatology

JF - Journal of the American Academy of Dermatology

SN - 0190-9622

IS - 6

ER -